Kawasaki disease natural history, complications and prognosis: Difference between revisions
(Created page with "__NOTOC__ {{Kawasaki disease}} {{CMG}}; {{AE}} ==Overview== If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestatio...") |
|||
| Line 15: | Line 15: | ||
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%. | Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%. | ||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
===Natural History=== | ===Natural History=== | ||
===Complications=== | ===Complications=== | ||
===Prognosis=== | ===Prognosis=== | ||
The [[cardiac]] complications are, by far, the most important aspect of the disease. Kawasaki disease can cause [[vasculitic]] changes (inflammation of blood vessels) in the [[coronary arteries]] and subsequent '''coronary artery [[aneurysm]]s'''. These aneurysms can lead to [[myocardial infarction]] ([[myocardial infarction|heart attack]]) even in young children. Overall, about 10–18% of children with Kawasaki disease develop coronary artery aneurysms<ref>{{cite journal | author = Belay E, Maddox R, Holman R, Curns A, Ballah K, Schonberger L | title = Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003. | journal = Pediatr Infect Dis J | volume = 25 | issue = 3 | pages = 245-9 | year = 2006 | id = PMID 16511388}}</ref>, with much higher prevalence among patients who are not treated early in the course of illness. Kawasaki disease is the most common cause of acquired heart disease among children in the United States. | |||
With early treatment, rapid recovery from the acute symptoms can be expected and the risk of coronary artery aneurysms greatly reduced. Untreated, the acute symptoms of Kawasaki disease are self-limited (''i.e.'' the patient will recover eventually), but the risk of coronary artery involvement is much greater. Overall, about 2% of patients die from complications of coronary vasculitis. Patients who have had Kawasaki disease should have an [[echocardiogram]] initially every few weeks, and then every 1–2 years to screen for progression of cardiac involvement. | |||
It is also not uncommon that a [[relapse]] of symptoms may occur soon after initial treatment with [[IVIG]]. This usually requires re-hospitalization and retreatment. Treatment with [[IVIG]] can cause allergic and non-allergic acute reactions, aseptic meningitis, [[fluid overload]] and, rarely, other serious reactions. Aspirin may increase the risk of bleeding from other causes and may be associated with Reye's syndrome. Overall, life-threatening complications resulting from therapy for Kawasaki disease are exceedingly rare, especially compared with the risk of non-treatment. | |||
==References== | ==References== | ||
Revision as of 13:41, 29 March 2018
|
Kawasaki disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
American Roentgen Ray Society Images of Kawasaki disease natural history, complications and prognosis |
|
FDA on Kawasaki disease natural history, complications and prognosis |
|
CDC on Kawasaki disease natural history, complications and prognosis |
|
Kawasaki disease natural history, complications and prognosis in the news |
|
Blogs on Kawasaki disease natural history, complications and prognosis |
|
Risk calculators and risk factors for Kawasaki disease natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
The cardiac complications are, by far, the most important aspect of the disease. Kawasaki disease can cause vasculitic changes (inflammation of blood vessels) in the coronary arteries and subsequent coronary artery aneurysms. These aneurysms can lead to myocardial infarction (heart attack) even in young children. Overall, about 10–18% of children with Kawasaki disease develop coronary artery aneurysms[1], with much higher prevalence among patients who are not treated early in the course of illness. Kawasaki disease is the most common cause of acquired heart disease among children in the United States.
With early treatment, rapid recovery from the acute symptoms can be expected and the risk of coronary artery aneurysms greatly reduced. Untreated, the acute symptoms of Kawasaki disease are self-limited (i.e. the patient will recover eventually), but the risk of coronary artery involvement is much greater. Overall, about 2% of patients die from complications of coronary vasculitis. Patients who have had Kawasaki disease should have an echocardiogram initially every few weeks, and then every 1–2 years to screen for progression of cardiac involvement.
It is also not uncommon that a relapse of symptoms may occur soon after initial treatment with IVIG. This usually requires re-hospitalization and retreatment. Treatment with IVIG can cause allergic and non-allergic acute reactions, aseptic meningitis, fluid overload and, rarely, other serious reactions. Aspirin may increase the risk of bleeding from other causes and may be associated with Reye's syndrome. Overall, life-threatening complications resulting from therapy for Kawasaki disease are exceedingly rare, especially compared with the risk of non-treatment.
References
- ↑ Belay E, Maddox R, Holman R, Curns A, Ballah K, Schonberger L (2006). "Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003". Pediatr Infect Dis J. 25 (3): 245–9. PMID 16511388.